dyslipidemia
DYSLIPIDEMIA
Dyslipidemia is having an abnormal amount of lipids or fats in the blood.
Lipid profile is obtained from an individual with diabetes mellitus, coronary heart disease, cerebrovascular disease, peripheral arterial disease or other coronary heart disease risk factors or from an individual with family history or clinical evidence of familial hypercholesterolemia.
Plasma lipids are total cholesterol, high-density lipoprotein cholesterol, trigylcerides, and low-density lipoprotein cholesterol.
Evaluation of lipid profile must be performed in parallel with the risk assessment of coronary heart disease.

Definition

  • An abnormality in lipoprotein metabolism that results in elevations of low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglycerides (TG), and/or non-high-density lipoprotein cholesterol (non-HDL-C) levels, or significantly reduced high-density lipoprotein cholesterol (HDL-C) levels
  • Increase in serum concentration of TC, LDL, TG or non-HDL-C is equivalent to increased risk for cardiovascular diseases

Etiology

  • Depends on the type of dyslipidemia
  • Hereditary disorders associated with dyslipidemia include familial hypertriglyceridemia, familial combined hyperlipidemia, familial dysbetalipoproteinemia, chylomicronemia
  • Secondary causes include diabetes mellitus, diet, alcohol intake, hypothyroidism, renal failure, medications (glucocorticoids, beta-blockers, thiazides, estrogen therapy)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 28 Sep 2015

Individuals with chronic ischaemic heart disease (IHD) and a small left ventricle and thick myocardium demonstrated higher levels of cardiac remodelling as opposed to those with a large ventricle and thin myocardium, contrary to the prevailing understanding, according to the DOPPLER-CIP study. 

18 Aug 2016
Chronic kidney disease (CKD), regardless of the stage, appears to have no direct effect on cardiovascular mortality within 180 days and 2 years from digoxin treatment initiation in treatment-naïve patients with non-valvular atrial fibrillation (AF), a Danish cohort study suggests.
Yesterday
The presence of target organ damage (TOD) in hypertension is more likely to result in blood pressure (BP) elevation, independently of the type of measurement (office or ambulatory, central or peripheral), according to a recent study. Central BP, even monitored during 24 hours, is not better correlated with TOD than peripheral BP.
19 Jun 2017
There is no evidence to support the association between neurofibromatosis type 1 and intracranial aneurysms, a new population-based study shows. Moreover, there is no rise in the incidence of aneurysmal subarachnoid haemorrhage in NF1 patients.